Zelira Therapeutics Ltd has released a press release.
Pause in Trading
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- EDCDM Technology License Agreement Update
- Zenivol Longitudinal, RWD Trial in Insomnia Results
- Hope 1 Longitudinal, Real-World Data Trial in ASD Results
- March 2022 Quarterly Activities Report
- Appendix 4D & FY22 Interim Financial Report
Later from Zelira Therapeutics
- Response to ASX Price Query
- Zenivol receives formal BfArM approval in Germany
- June 2022 Quarterly Activities Report
- Response to ASX Aware Query
- ZLDs Diabetic Nerve Pain Drug Trial Two-Thirds Enrolled
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics